ARVINAS INC. - COMMON

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

04 апр 2025 06:00:08 Источник Nasdaq GlobeNewswire

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

27 мар 2025 06:00:24 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

11 мар 2025 05:45:00 Источник Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 мар 2025 15:05:09 Источник Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

11 фев 2025 06:00:04 Источник Nasdaq GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

03 фев 2025 06:00:49 Источник Nasdaq GlobeNewswire

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

10 янв 2025 06:00:19 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

10 дек 2024 08:05:00 Источник Nasdaq GlobeNewswire

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

27 ноя 2024 06:00:31 Источник Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

25 ноя 2024 16:35:18 Источник Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 ноя 2024 06:00:13 Источник Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

30 окт 2024 06:00:45 Источник Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

22 окт 2024 15:05:06 Источник Nasdaq GlobeNewswire

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

21 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

29 авг 2024 06:00:48 Источник Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

30 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

24 июн 2024 15:37:13 Источник Nasdaq GlobeNewswire

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21 июн 2024 06:00:51 Источник Nasdaq GlobeNewswire

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

17 июн 2024 06:00:03 Источник Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

03 июн 2024 15:30:00 Источник Nasdaq GlobeNewswire